irinotecan has been researched along with Rhabdomyosarcoma, Embryonal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, H; Li, W; Qu, S; Yao, Y | 1 |
| Cassinelli, G; De Cesare, M; Lanzi, C; Zaffaroni, N; Zuco, V | 1 |
2 other study(ies) available for irinotecan and Rhabdomyosarcoma, Embryonal
| Article | Year |
|---|---|
An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report.
Topics: Adult; Child; Humans; Ifosfamide; Irinotecan; Male; Perineum; Rhabdomyosarcoma; Rhabdomyosarcoma, Embryonal; Young Adult | 2022 |
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Topics: Activation, Metabolic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Polo-Like Kinase 1; Prodrugs; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proteolysis; Proto-Oncogene Proteins; Pteridines; Rhabdomyosarcoma, Embryonal; Sarcoma, Ewing; Skin Neoplasms; Topoisomerase I Inhibitors; Ubiquitination; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2015 |